The Company's Board of Director's resolution on
convening 2022 1st extraordinary stockholder meeting
Date of events
2022/06/14
To which item it meets
paragraph 17
Statement
1.Date of the board of directors resolution:2022/06/14
2.Extraordinary shareholders' meeting date:2022/08/30
3.Extraordinary shareholders'' meeting location:
No.2, Gongye Rd., Guantian Dist., Tainan City
(Guantian Industrial Partk Service Center Meeting Room)
4.Special shareholders meeting will be held by means of
(physical shareholders meeting/ visual communication
assisted shareholders meeting /visual communication
shareholders meeting):Physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:NA
6.Cause for convening the meeting II.Acknowledged matters:NA
7.Cause for convening the meeting III.Matters for Discussion:
(1)To acquire 100% common share of TWi Pharmaceuticals, Inc.
8.Cause for convening the meeting IV.Election matters:NA
9.Cause for convening the meeting V.Other Proposals:NA
10.Cause for convening the meeting VI.Extemporary Motions:NA
11.Book closure starting date:2022/08/01
12.Book closure ending date:2022/08/30
13.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 13:42:09 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
